MagVenture Inc., a provider of transcranial magnetic stimulation, has received clearance from the US Food and Drug Administration for a new protocol that cuts the time of each treatment session down to 3 minutes, the company announced.
Patients with major depressive disorder (MDD) treated with the anticonvulsant ezogabine demonstrated a significant drop in depressive symptoms and an increase in resilience in a small trial described online in Molecular Psychiatry.
Cognitive behavioral humanistic and interpersonal training (CATCH-IT) may be better than health education as a primary care intervention to reduce risk in adolescents with subsyndromal depression, researchers say.
The benefits of Sage Therapeutics Inc's experimental treatment for postpartum depression outweigh risks, an advisory panel to the U.S. Food and Drug Administration said.
An advisory panel to the U.S. Food and Drug Administration on Thursday voted against approving Alkermes Plc's treatment for depression in patients with an inadequate response to standard antidepressant therapies.
Through a scan of social media posts, an algorithm was able to predict which individuals were later diagnosed with depression, according to a study published online.